Categories: BioTechDesignDrugResearchScienceUniversity
Aukera Therapeutics is a preclinical-stage biotech spin-off from the University of Basel, emerged from pioneering research on mTOR biology. We specialize in leveraging protein design to drive drug discovery on complex targets. Our lead program focuses on developing a first-in-class, fully selective mTORC1 inhibitor, addressing neurological disorders and cancers. We are committed to translating cutting-edge science into transformative therapies that can significantly impact patient lives.
Investors 1
Mentions in press and media 2
| Date | Title | Description |
| 26.03.2025 | Venture Leaders Biotech 2025 cohort revealed |
After reviewing over 70 applications, the jury of investors and biotech experts selected the ten startups to participate in the Boston roadshow, one of the world’s leading life science hubs. The Venture Leaders program will allow the selec... |
| 17.02.2025 | Healthtech startups set for growth |
The Innosuisse Certificate serves as a mark of excellence, indicating that a company has demonstrated growth and success in competitive markets. To obtain this certification, companies which went through the Innosuisse Start-up Coachingmus... |
Reviews 0
